In this @-week , multicentre , double-blind , placebo-controlled , parallel-group , phase @ study , patients with a primary GAD diagnosis were randomised to receive placebo ( n = @ ) , vortioxetine @ mg , vortioxetine @ mg , vortioxetine @ mg or duloxetine @ mg once daily ( n = @ each ) .